Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. (TMCI) is a leader in 3D bunion correction and foot/ankle surgical solutions, delivering innovative technologies like the Lapiplasty system. This page provides timely updates on TMCI’s advancements in orthopedic medical devices, financial milestones, and clinical research.
Access press releases covering product launches, regulatory approvals, and partnerships that shape surgical practices. Investors will find earnings reports and strategic updates, while medical professionals can track procedural innovations and training opportunities.
Our curated news collection ensures you stay informed about TMCI’s contributions to reproducible surgical outcomes and cost-effective patient care. Content is verified for accuracy and relevance, offering a neutral perspective on company developments.
Bookmark this page for streamlined access to TMCI’s latest achievements in addressing complex deformities through evidence-based solutions. Regularly updated to reflect the company’s commitment to advancing orthopedic care.
Treace Medical Concepts (TMCI) announced that CEO John T. Treace and CFO Mark Hair will join a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at approximately 4:15 PM ET. This discussion will focus on the company’s innovative Lapiplasty® 3D Bunion Correction™ procedure, designed to improve surgical treatment for bunions. A live webcast and replay will be available on the company's investor relations website.
Treace Medical Concepts (Nasdaq: TMCI), a pioneering orthopaedic medical device company, announced new data will be presented at the 2021 AOFAS Annual Meeting on September 22-25. The presentation will feature an interim analysis from the ALIGN3D™ clinical study, which evaluates the Lapiplasty® 3D Bunion Correction™ procedure. Lead author Dr. Dane Wukich will discuss outcomes from this multicenter study, focusing on patient recovery and radiographic results. The study aims to confirm effective bunion correction over a 24-month follow-up with 173 enrolled patients.
Treace Medical Concepts (TMCI) reported Q2 2021 revenue of $20.7 million, marking a 167% increase compared to Q2 2020. The gross margin improved to 80.9%, up 780 basis points year-over-year. The rise in revenue is attributed to more Lapiplasty® procedure kits sold and a growing customer base. Despite higher revenues, the net loss for the quarter increased to ($5.1 million), or ($0.10) per share, compared to ($2.1 million), or ($0.06) per share last year. The company anticipates full-year revenue between $90 million and $95 million, reflecting a growth of 57% to 65%.
Treace Medical Concepts (NasdaqGS: TMCI) will announce its second quarter 2021 financial results on August 5, 2021, after the market closes. A conference call led by management will commence at 4:30 p.m. ET to discuss the results. The company is known for its Lapiplasty® 3D Bunion Correction™ system, which addresses bunion deformities. Investors can join the call by dialing (888) 708-0264 or (720) 405-2122 for international access. The call will also be webcasted live and archived on their investor relations website.
Treace Medical Concepts (TMCI) reported significant first-quarter 2021 financial results, achieving $18.7 million in revenue, a 66.2% increase from last year. Gross margin improved to 82.2%, up 340 basis points year-over-year, driven by higher sales of the Lapiplasty Procedure Kits. Despite a net loss of $2.6 million or ($0.07) per share, the company anticipates a full-year revenue range of $87 million to $92 million, indicating 52% to 60% growth from fiscal 2020. Cash and equivalents stood at $16.2 million as of March 31, 2021, excluding IPO proceeds.
Treace Medical Concepts (TMCI) announced positive interim results from the ALIGN3D clinical study at the ACFAS Annual Scientific Conference. The study evaluated 128 participants undergoing the Lapiplasty 3D Bunion Correction procedure. Key findings include an early weight-bearing average of 8.3 days, a 1.4% recurrence rate at 12 months, and significant improvements in patient-reported pain and quality of life. The study aims to assess long-term outcomes and has completed enrollment, with final results expected in 2023.
Treace Medical Concepts (TMCI) announced it will release its Q1 2021 financial results on May 25, 2021, after market close. A conference call hosted by management will take place at 4:30 p.m. ET to discuss these results. Investors can access the call by dialing (833) 730-3977 (domestic) or (720) 405-2122 (international) with Conference ID: 1157038. The company specializes in surgical treatments for bunions through its patented Lapiplasty® 3D Bunion Correction™ system, aimed at enhancing patient recovery and addressing the root causes of bunion deformities.
Treace Medical Concepts (TMCI) announced that interim results of its ALIGN3D™ clinical study will be presented at the ACFAS Scientific Conference on May 19, 2021. The study evaluates the effectiveness of the Lapiplasty® 3D Bunion Correction™ in treating hallux valgus, involving 173 patients across seven sites. Key endpoints include recurrence of the bunion deformity and patient-reported outcomes after two years. The final follow-up for primary endpoints is expected in the first half of 2023, indicating ongoing commitment to advancing surgical treatment standards.
Treace Medical Concepts, Inc. (Nasdaq: TMCI) announced its upsized initial public offering pricing of 11,250,000 shares at $17.00 each, aiming for gross proceeds of approximately $106.3 million. Of these shares, 6,250,000 will be sold by Treace, while 5,000,000 are from selling stockholders. Additionally, underwriters have a 30-day option to purchase up to 1,687,500 additional shares. Trading is set to commence on April 23, 2021, with the closing expected by April 27, 2021, following standard conditions.
Treace Medical Concepts (Nasdaq: TMCI) announced an upsized initial public offering (IPO) of 11,250,000 shares, priced at $17.00 each, aiming to raise approximately $106.3 million before expenses. Of these, 6,250,000 shares are offered by Treace while 5,000,000 shares are from selling stockholders. The offering includes a 30-day option for underwriters to purchase an additional 1,687,500 shares. Trading on the Nasdaq is set to start on April 23, 2021, with the closing anticipated on April 27, 2021, pending customary conditions.
